Lindsay Harrison, MD
Endocrinology, Diabetes & Metabolism · Austin, TXNPI 1598964702
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $94,275 of the $103,301 with a category attached, or 91.3%. Lilly USA, LLC accounts for 96.6% of it on its own, with 42 other manufacturers making up the rest. Among endocrinology, diabetes & metabolism clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 331 payments — averaging $312.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$100K
- Novo Nordisk$523
- Abbott$320
- BETA Bionics, Inc.$297
- Amgen$258
- Dexcom, Inc.$197
- plus $2K from 37 others
Across 227 payments — averaging $9423.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$1.6M
- AbbVie$284K
- BD$195K
- Dexcom, Inc.$26K
- Sanofi US Services Inc.$11K
What the payments were for
- Speaking & faculty fees$94,27591%
- Travel & lodging$3,3803%
- Food & beverage$5,4895%
- Education$1380%
- Gifts$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$80,289
- iLet Bionic Pancreas$312
How this compares
$103,301 in reported general payments places this provider in the 90th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 343 | $439,553 |
| OzempicSemaglutide | 176 | $240,540 |
| TrulicityDulaglutide | 98 | $184,273 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 99 | $132,056 |
| FarxigaDapagliflozin Propanediol | 70 | $89,108 |
| JardianceEmpagliflozin | 50 | $73,260 |
| Teriparatide | 24 | $59,283 |
| Tresiba Flextouch U-100Insulin Degludec | 59 | $46,199 |
| Xigduo XrDapaglifloz Propaned/Metformin | 42 | $45,623 |
| TymlosAbaloparatide | 16 | $41,973 |
| RybelsusSemaglutide | 15 | $34,370 |
| Repatha SureclickEvolocumab | 30 | $32,562 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 37 | $32,539 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 48 | $31,541 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $24,216 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $99,817 | $628,446461 claims |
| Novo NordiskOzempic, Rybelsus | $523 | $274,910191 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance | $41 | $205,316149 claims |
| AstraZenecaFarxiga | $84 | $89,10870 claims |
| Alvogen IncTeriparatide | $24 | $59,28324 claims |
| Radius Health, Inc.Tymlos | $81 | $41,97316 claims |
| AbbVieSynthroid, Armour Thyroid | $86 | $24,043296 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Austin
- Thomas BlevinsAustin$904K
- Lance SloanLufkin$1.7M
- Pablo MoraDallas$1.3M
- Robert HoodBeaumont$1.3M
- Eduardo LunaEdinburg$1.3M
- Steve FordanDallas$1.2M
- Rosemarie LajaraPlano$1.2M
- Saleemah FahmiDallas$1.2M
- Julio RosenstockDallas$1.2M
- Rocio HarbisonHouston$989K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.